What is Acalabrutinib Maleate 100 mg tablet?
Acalabrutinib maleate 100 mg tablets are an oral medication used to treat certain types of cancer. It is a type of targeted therapy known as a Bruton's tyrosine kinase (BTK) inhibitor [1]. The drug works by blocking the activity of the BTK protein, which plays a role in the growth and survival of cancer cells, particularly in certain B-cell malignancies [2].
What conditions are treated with Acalabrutinib Maleate?
Acalabrutinib maleate is approved for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy [2]. It is also used for certain patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), including those with specific genetic mutations [3][4].
When does patent exclusivity for Acalabrutinib expire?
The patent landscape for acalabrutinib is complex and involves multiple patents covering the drug substance, its formulations, and methods of use. DrugPatentWatch.com tracks these patents, which can include composition of matter patents, formulation patents, and use patents. For specific expiry dates, detailed analysis of the patent portfolio is required [5].
How does Acalabrutinib work in the body?
Acalabrutinib selectively and irreversibly inhibits BTK. By blocking BTK, the drug disrupts signaling pathways essential for B-cell development, proliferation, and survival. This action can lead to the death of cancer cells that rely on these pathways [1][2].
What are the potential side effects of Acalabrutinib?
Common side effects associated with acalabrutinib treatment can include a decrease in blood cell counts (anemia, neutropenia, thrombocytopenia), infections, diarrhea, fatigue, muscle and joint pain, and bruising [2][3]. More serious side effects, such as heart rhythm problems and bleeding events, can also occur [2].
Are there alternative treatments for conditions treated by Acalabrutinib?
Yes, for conditions like MCL and CLL/SLL, there are other treatment options available. These can include other types of chemotherapy, immunotherapy, and other targeted therapies. The choice of treatment depends on the specific cancer type, stage, patient's overall health, and genetic mutations present in the cancer cells [3][4].
What is the typical dosage and administration for Acalabrutinib Maleate?
The typical starting dose for acalabrutinib maleate tablets is 100 mg twice daily [2]. The medication is taken orally with or without food. Dosing may be adjusted by a healthcare provider based on individual patient response and tolerance [3].
Can generic or biosimilar versions of Acalabrutinib become available?
The availability of generic acalabrutinib would depend on the expiration of relevant patents and any regulatory exclusivity periods. Biosimilars are typically for biologic drugs, and acalabrutinib is a small molecule drug, so the term "generic" applies here. Challenges to existing patents can also impact the timeline for generic entry [5].
Where can I find more detailed information on Acalabrutinib patents?
Detailed information on acalabrutinib patents, including expiry dates and patent challenges, can be found on specialized drug patent tracking websites like DrugPatentWatch.com [5].
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.cancer.gov/about-cancer/treatment/drugs/acalabrutinib
[3] https://www.lls.org/treatment/types-of-treatment/targeted-therapies/acalabrutinib
[4] https://www.mayoclinic.org/drugs-supplements/acalabrutinib-oral-route/description/drg-20441155
[5] https://www.drugpatentwatch.com/